Distribution of fenofibric acid in lipoprotein fractions of patients
Jazyk angličtina Země Francie Médium print
Typ dokumentu klinické zkoušky, časopisecké články
PubMed
9725495
DOI
10.1007/bf03189353
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- fenofibrát analogy a deriváty krev farmakokinetika MeSH
- hypolipidemika krev farmakokinetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipoproteiny chemie MeSH
- miniaturní prasata MeSH
- prasata MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- Názvy látek
- fenofibrát MeSH
- fenofibric acid MeSH Prohlížeč
- hypolipidemika MeSH
- lipoproteiny MeSH
The antidyslipidemic agent fenofibrate (procetofen) is hydrolysed in vivo to its main active metabolite--fenofibric (procetofenic) acid. This metabolite is usually determined in pharmacokinetic studies, because plasma concentrations of fenofibrate are practically undetectable. Presented study is focussed on the distribution of fenofibric acid into lipoprotein (VLDL, LDL, IDL and HDL) fractions of human and (for comparison) minipig blood plasma, which has not been studied yet. In order to obtain more accurate results, a new HPLC method based on the use of newly synthetized internal standards was developed. Four homologues of fenofibric acid prepared have identical chromophoric part of their molecules and hence the same UV spectra as fenofibric acid. From this point of view, these standards are more suitable for determination of fenofibric acid than the formerly used ones--naproxen or bezafibrate. Fenofibric acid levels in the high density lipoprotein fraction has been shown to be significantly higher (in both human and minipig plasma) than in the other lipoprotein fractions. This fact may be explained by higher affinity of the fenofibric acid to proteins constituting major part of the high density lipoprotein fraction.
Zobrazit více v PubMed
Arzneimittelforschung. 1976;26(5):885-9 PubMed
Arzneimittelforschung. 1976;26(5):901-6 PubMed
Am J Med. 1987 Nov 27;83(5B):21-5 PubMed
Drugs. 1990 Aug;40(2):260-90 PubMed
J Chromatogr. 1982 Jan 8;227(1):219-22 PubMed
Arzneimittelforschung. 1976;26(5):896-901 PubMed
Drug Metab Dispos. 1990 Jan-Feb;18(1):115-20 PubMed
Arzneimittelforschung. 1976;26(5):906-9 PubMed
J Chromatogr. 1976 Aug 4;123(2):463-7 PubMed
J Chromatogr. 1978 Jan 1;145(1):160-4 PubMed
Chirality. 1989;1(3):197-201 PubMed
J Chromatogr. 1986 Dec 19;383(2):419-24 PubMed
Drug Metab Dispos. 1988 Mar-Apr;16(2):302-9 PubMed
Eur J Clin Pharmacol. 1988;34(1):25-8 PubMed
Pharmacol Ther. 1985;29(2):157-204 PubMed
Arzneimittelforschung. 1976;26(5):889-94 PubMed
